NR4A1 and pancreatic neoplasm: Although tamoxifen administered alone has repeatedly been shown to not exert a significant effect against pancreatic cancer in clinical studies (22), combination therapy comprising tamoxifen with other chemotherapeutic agents has been shown to be effective in phase II trials, regardless of the hormone receptor status of the pancreatic tumor (24,25).